Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment-Reference-Cited by-同舟云学术

Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

Published:2017-05 Issue:5 Volume:7 Page:e565-e565
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Paulus A,Akhtar S,Yousaf H,Manna A,Paulus S M,Bashir Y,Caulfield T R,Kuranz-Blake M,Chitta K,Wang X,Asmann Y,Hudec R,Springer W,Ailawadhi S,Chanan-Khan A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201740.pdf

Reference53 articles.

1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 110–115.

2. Oza A, Rajkumar SV . Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J 2015; 5: e296.

3. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 2015; 372: 1430–1440.

4. Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia. Leukemia 2015; 29: 169–176.

5. Young RM, Staudt LM . Ibrutinib treatment of CLL: the cancer fights back. Cancer Cell 2014; 26: 11–13.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas;Acta Pharmacologica Sinica;2024-06-04

2. Optimizing BTK Inhibition in Waldenström Macroglobulinemia;Journal of the National Comprehensive Cancer Network;2024-05

3. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27

4. Current approach to Waldenström macroglobulinemia;Blood Reviews;2023-11

5. Monoclonal antibodies for treatment of cold agglutinin disease;Expert Opinion on Biological Therapy;2023-05-04